BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Georgopoulos S, Papastergiou V. An update on current and advancing pharmacotherapy options for the treatment of H. pylori infection. Expert Opin Pharmacother 2021;22:729-41. [PMID: 33131337 DOI: 10.1080/14656566.2020.1845649] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Miri AH, Kamankesh M, Llopis-lorente A, Liu C, Wacker MG, Haririan I, Asadzadeh Aghdaei H, Hamblin MR, Yadegar A, Rad-malekshahi M, Zali MR. The Potential Use of Antibiotics Against Helicobacter pylori Infection: Biopharmaceutical Implications. Front Pharmacol 2022;13:917184. [DOI: 10.3389/fphar.2022.917184] [Reference Citation Analysis]
2 Sousa C, Ferreira R, Azevedo NF, Oleastro M, Azeredo J, Figueiredo C, Melo LDR. Helicobacter pylori infection: from standard to alternative treatment strategies. Crit Rev Microbiol 2021;:1-21. [PMID: 34569892 DOI: 10.1080/1040841X.2021.1975643] [Reference Citation Analysis]
3 Narczyk M, Wojtyś MI, Leščić Ašler I, Žinić B, Luić M, Jagusztyn-Krynicka EK, Štefanić Z, Bzowska A. Interactions of 2,6-substituted purines with purine nucleoside phosphorylase from Helicobacter pylori in solution and in the crystal, and the effects of these compounds on cell cultures of this bacterium. J Enzyme Inhib Med Chem 2022;37:1083-97. [PMID: 35437103 DOI: 10.1080/14756366.2022.2061965] [Reference Citation Analysis]
4 Xirouchakis E, Georgopoulos SD. Evaluating treatments with rifabutin and amoxicillin for eradication of Helicobacter pylori infection in adults: a systematic review. Expert Opin Pharmacother 2021;:1-10. [PMID: 34595999 DOI: 10.1080/14656566.2021.1982894] [Reference Citation Analysis]
5 Rueda-Robles A, Rubio-Tomás T, Plaza-Diaz J, Álvarez-Mercado AI. Impact of Dietary Patterns on H. pylori Infection and the Modulation of Microbiota to Counteract Its Effect. A Narrative Review. Pathogens 2021;10:875. [PMID: 34358024 DOI: 10.3390/pathogens10070875] [Reference Citation Analysis]
6 Caldas M, Pérez-Aisa Á, Tepes B, Keco-Huerga A, Bujanda L, Lucendo AJ, Rodrigo L, Vaira D, Fernández-Salazar L, Huguet JM, Pérez-Lasala J, Jurecic NB, Fadeenko G, Barrio J, Areia M, Ortuño J, Pellicano R, Leja M, Molina-Infante J, Bogomolov P, Alekseenko S, Domínguez-Cajal M, Gómez-Camarero J, Ntouli V, Martínez-Domínguez SJ, Ruiz-Zorrilla R, Núñez O, Sarsenbaeva AS, Almela P, Phull P, Espada M, Puig I, Nyssen OP, Mégraud F, O'Morain C, Gisbert JP; the Hp-EuReg Investigators. The Role of Statins on Helicobacter pylori Eradication: Results from the European Registry on the Management of H. pylori (Hp-EuReg). Antibiotics (Basel) 2021;10:965. [PMID: 34439015 DOI: 10.3390/antibiotics10080965] [Reference Citation Analysis]
7 Jia J, Zhang C, Liu Y, Huang Y, Bai Y, Hang X, Zeng L, Zhu D, Bi H. Armeniaspirol A: a novel anti-Helicobacter pylori agent. Microb Biotechnol 2021. [PMID: 33780131 DOI: 10.1111/1751-7915.13807] [Reference Citation Analysis]
8 Krzyżek P, Junka A, Słupski W, Dołowacka-Jóźwiak A, Płachno BJ, Sobiecka A, Matkowski A, Chodaczek G, Płusa T, Gościniak G, Zielińska S. Antibiofilm and Antimicrobial-Enhancing Activity of Chelidonium majus and Corydalis cheilanthifolia Extracts against Multidrug-Resistant Helicobacter pylori. Pathogens 2021;10:1033. [PMID: 34451497 DOI: 10.3390/pathogens10081033] [Reference Citation Analysis]
9 Viazis N, Argyriou K, Kotzampassi K, Christodoulou DK, Apostolopoulos P, Georgopoulos SD, Liatsos C, Giouleme O, Koustenis K, Veretanos C, Stogiannou D, Moutzoukis M, Poutakidis C, Mylonas II, Tseti I, Mantzaris GJ. A Four-Probiotics Regimen Combined with A Standard Helicobacter pylori-Eradication Treatment Reduces Side Effects and Increases Eradication Rates. Nutrients 2022;14:632. [PMID: 35276991 DOI: 10.3390/nu14030632] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
10 Martin-Nuñez GM, Cornejo-Pareja I, Clemente-Postigo M, Tinahones FJ. Gut Microbiota: The Missing Link Between Helicobacter pylori Infection and Metabolic Disorders? Front Endocrinol (Lausanne) 2021;12:639856. [PMID: 34220702 DOI: 10.3389/fendo.2021.639856] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Keikha M, Karbalaei M. Probiotics as the live microscopic fighters against Helicobacter pylori gastric infections. BMC Gastroenterol 2021;21:388. [PMID: 34670526 DOI: 10.1186/s12876-021-01977-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
12 Ben Ghezala I, Luu M, Bardou M. An update on drug-drug interactions associated with proton pump inhibitors. Expert Opin Drug Metab Toxicol 2022. [PMID: 35787720 DOI: 10.1080/17425255.2022.2098107] [Reference Citation Analysis]